中恒集团：控股孙公司纳米炭铁混悬注射液联合放疗II期临床试验获得伦理批件

Core Viewpoint - Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has successfully passed the ethical review for its independently developed "Nano Carbon Iron Suspension Injection," marking the entry into Phase II clinical trials in collaboration with radiotherapy [1] Group 1 - The "Nano Carbon Iron Suspension Injection" has received formal approval from the Clinical Trial Ethics Review Committee [1] - The clinical trials are being conducted at West China Hospital of Sichuan University [1] - This development signifies a significant advancement in the company's research and development efforts in the pharmaceutical sector [1]